Cullen/Frost Bankers’s Amneal Pharmaceuticals AMRX Stock Holding History

Cullen/Frost Bankers’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.61K	Hold	151	–	–	﹤0.01%	1267
2026 Q1	$1.88K	Hold	151	–	–	﹤0.01%	1258
2025 Q4	$1.9K	Hold	151	–	–	﹤0.01%	1255
2025 Q3	$1.51K	Buy	+151	New	+$1.35K	﹤0.01%	1243
2021 Q1	–	Sell	-4,400	Closed	-$20K	–	1064
2020 Q4	$20K	Hold	4,400	–	–	﹤0.01%	841
2020 Q3	$17K	Hold	4,400	–	–	﹤0.01%	847
2020 Q2	$21K	Buy	+4,400	New	+$18.1K	﹤0.01%	805

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFC

Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Cullen/Frost Bankers's AMRX Position: Q2 2026 in Review

Cullen/Frost Bankers held its Amneal Pharmaceuticals (AMRX) position steady in Q2 2026 at 151 shares worth $2.61K. The position accounts for ﹤0.01% of the portfolio, ranked #1267.

Cullen/Frost Bankers first reported a position in AMRX in Q2 2020 and has held it in 7 quarters since. The position peaked at $21K in Q2 2020. 124 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Cullen/Frost Bankers held 151 shares of Amneal Pharmaceuticals worth $2.61K as of Q2 2026.
Cullen/Frost Bankers left its Amneal Pharmaceuticals share count unchanged in Q2 2026.
Amneal Pharmaceuticals made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #1267 holding.
Cullen/Frost Bankers first reported a position in Amneal Pharmaceuticals in Q2 2020 and has held it in 7 quarters since.
Cullen/Frost Bankers's Amneal Pharmaceuticals position peaked at $21K in Q2 2020.
124 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.